Betibeglogene autotemcel (beti-cel) gene therapy for the treatment of Transfusion-Dependent β-Thalassemia (TDT): Updated long-term efficacy and safety results

被引：0

作者：

Kulozik, A. E. ^{[1
]}

Thuret, I ^{[2
]}

Thompson, A. A. ^{[3
]}

Kwiatkowski, J. L. ^{[4
]}

Porter, J. B. ^{[5
]}

Hongeng, S. ^{[6
]}

Yannaki, E. ^{[7
]}

Sauer, M. G. ^{[8
]}

Thrasher, A. J. ^{[9
]}

Lal, A.

Du, L. ^{[10
]}

Colvin, R. A. ^{[11
]}

Walters, M. C. ^{[12
]}

Locatelli, F. ^{[13
]}

机构：

[1] Heidelberg Univ, Univ Med Ctr Children & Adolescents, Heidelberg, Germany

[2] Marseille Univ, Dept Pediat Hematol, Marseille, France

[3] Feinberg Sch Med, Hematol Sect, Chicago, IL USA

[4] Childrens Hosp Philadelphia, Div Hematol, Philadelphia, PA USA

[5] UCL, Dept Haematol, London, England

[6] Ramathibodi Hosp, Dept Pediat, Fac Med, Bangkok, Thailand

[7] G Papanicolaou Hosp, Hematol Dept Hematopoiet Cell Transplantat Unit, Gene & Cell Therapy Ctr, Thessaloniki, Greece

[8] Hannover Med Sch, Pediat Hematol & Oncol, Hannover, Germany

[9] Great Ormond St Hosp Sick Children, London, England

[10] UCSF Benioff Childrens Hosp, Oakland, CA USA

[11] Bluebird Bio Inc, Cambridge, England

[12] Univ Calif San Francisco, San Francisco, CA 94143 USA

[13] Osped Pediat Bambino Gesu, Dept Pediat Hematol Oncol, Rome, Italy

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V293

引用

页码：8 / 9

页数：2

共 50 条

[41] Safety and Efficacy of LentiGlobin Gene Therapy for Transfusion-Dependent β-thalassemia (TDT) in Patients with non-β0/β0 Genotypes: Interim results from the HGB-204 (Northstar) and HGB-207 (Northstar-2) Trials
Porter, J. B.
Walters, M. C.
Kwiatkowski, J. L.
Rasko, J. E. J.
Hongeng, S.
Schiller, G. J.
Locatelli, F.
Sauer, M.
Thrasher, A.
Thuret, I.
Yannaki, E.
Elliot, H.
Deary, B.
Gayron, M.
Ramirez-Santiago, A.
Thompson, A. A.
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 30 - 30
[42] EU Approval for first CRISPR/Cas9 Gene-editing based Therapy Exagamglogenic autotemcel for the Treatment of Sickle Cell Disease and transfusion-dependent Beta-Thalassemia
Ruedesheim, Sabine M.
TRANSFUSION MEDICINE AND HEMOTHERAPY, 2024, 51 (02) : 127 - 127
[43] EU Approval for first CRISPR/Cas9 Gene-Editing based Therapy Exagamgiogenic Autotemcel for the Treatment of Sickle Cell Disease and transfusion-dependent Beta-Thalassemia
不详
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (04) : 162 - 162
[44] Long-term safety and efficacy of hydroxyurea in patients with non-transfusion-dependent β-thalassemia: a comprehensive single-center experience
Karimi, Mehran
Zarei, Tahereh
Bahmanimehr, Ardeshir
Aramesh, Azam
Daryanoush, Saeed
Haghpanah, Sezaneh
ANNALS OF HEMATOLOGY, 2021, 100 (12) : 2901 - 2907
[45] Long-term safety and efficacy of hydroxyurea in patients with non-transfusion-dependent β-thalassemia: a comprehensive single-center experience
Mehran Karimi
Tahereh Zarei
Ardeshir Bahmanimehr
Azam Aramesh
Saeed Daryanoush
Sezaneh Haghpanah
Annals of Hematology, 2021, 100 : 2901 - 2907
[46] LONG-TERM ASSESSMENT OF EFFICACY AND SAFETY OF L1, AN ORAL IRON CHELATOR, IN TRANSFUSION DEPENDENT THALASSEMIA - INDIAN TRIAL
AGARWAL, MB
GUPTE, SS
VISWANATHAN, C
VASANDANI, D
RAMANATHAN, J
DESAI, N
PUNIYANI, RR
CHHABLANI, AT
BRITISH JOURNAL OF HAEMATOLOGY, 1992, 82 (02) : 460 - 466
[47] EFFICACY AND SAFETY OF LENTIGLOBIN GENE THERAPY IN PATIENTS WITH TRANSFUSION-DEPENDENT β-THALASSEMIA AND NON-β0/β0 GENOTYPES: UPDATED RESULTS FROM THE COMPLETED PHASE 1/2 NORTHSTAR AND ONGOING PHASE 3 NORTHSTAR-2 STUDIES
Rasko, J.
Walters, M.
Kwiatkowski, J.
Hongeng, S.
Porter, J.
Sauer, M.
Thrasher, A.
Thuret, I.
Schiller, G.
Elliot, H.
Deary, B.
Chen, Y.
Tao, G.
Asmal, M.
Locatelli, F.
Thompson, A.
CYTOTHERAPY, 2019, 21 (05) : S14 - S14
[48] Interim results from the phase 3 Northstar-2 and Northstar-3 studies of LentiGlobin gene therapy for the treatment of transfusion-dependent β-thalassemia
Kunz, J.
Locatelli, F.
Kulozik, A.
Sauer, M.
Kwiatkowski, J.
Porter, J.
Thuret, I.
Hongeng, S.
Lal, A.
Thrasher, A.
Yannaki, E.
Elliot, H.
Tao, G.
Chen, Y.
Colvin, R.
Walters, M.
Thompson, A.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 301 - 301
[49] Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia (vol 100, pg 1566, 2002)
Wanless
BLOOD, 2003, 101 (07) : 2460 - 2460
[50] Updated results from the ongoing northstar-2 (HGB-207) trial of lentiglobin gene therapy in patients with transfusion-dependent β-thalassemia and non-β0/β0 genotypes
Locatelli, Franco
Thompson, Alexis
Kwiatkowski, Janet
Hongeng, Suradej
Porter, John
Sauer, Martin
Thrasher, Adrian
Thuret, Isabelle
Elliot, Heidi
Tao, Ge
Asmal, Mohammed
Walters, Mark
BONE MARROW TRANSPLANTATION, 2019, 54 : 75 - 76

← 1 2 3 4 5 →